Spire Healthcare has published the scheme document for its board-backed Takeover by Tulip UK Bidco, a vehicle owned by a consortium including Toscafund, THCP and Ares. Shareholders will vote on 30 October 2026 on the 250p-a-share cash offer, and the document also sets out a rollover alternative.

Spire Healthcare publishes its scheme document

In an announcement released at 13:48 on 29 September 2026, Spire Healthcare Group plc (LSE:SPI) announced the publication of the scheme document for its proposed Acquisition by Tulip UK Bidco Limited ("Bidco"). The announcement describes Bidco as "a newly formed company indirectly owned by a consortium including: (i) funds managed or advised by Toscafund Asset Management LLP; (ii) funds managed or advised by THCP Advisory Limited; and (iii) funds managed or advised by Ares Management Limited".

The deal is to be carried out through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006, although Bidco keeps the option to switch to a takeover offer. The document sets the Court Meeting for 12:00 p.m. and the General Meeting for 12:15 p.m., both on 30 October 2026.

The offer terms and the board's position

The scheme document announcement notes that on 5 September 2026 the Spire directors and the Bidco board announced agreement on a final cash offer backed by the Spire board. That Rule 2.7 announcement set the cash offer at 250 pence per share. It valued Spire at about £1,026.5 million on a fully diluted basis and gave an Enterprise value of about £2,307.6 million.

Bidco is also offering an alternative, open to eligible shareholders, of 2.5 rollover securities per share. The 5 September announcement capped it at 28 million shares in aggregate, around 8.5% of the scheme shares. The Spire directors back the cash offer and are asking shareholders to vote in favour, having been advised that "the terms of the Cash Offer are fair and reasonable". On the alternative, they say they are unable to form a view on whether its terms are fair and reasonable, and are therefore taking no position on it.

Why the scheme document matters for this FTSE 250 stock

Publishing the scheme document starts the formal voting process for the proposed takeover of Spire, a FTSE 250 constituent. The scheme needs approval from scheme shareholders at the Court Meeting, the passing of the resolution at the General Meeting, and then the court's sanction. The Rule 2.7 announcement also listed FCA approval of the change in control of regulated entities in the Spire group among the conditions.

Risks and conditions to watch

The directors' irrevocable undertakings cover only around 0.4% of the issued share capital, so the result will depend on the wider Shareholder base. The court hearing and the effective date are both shown only as expected in the fourth quarter of 2026 or the first quarter of 2027, with a latest implementation date of 11:59 p.m. on 4 March 2027. The 5 September announcement also said Bidco could reduce the cash consideration by any dividends declared with record dates before the effective date. Shareholders who choose the rollover alternative would receive rollover securities on terms the board has not endorsed.

What investors may watch next

The proxy deadlines are 12:00 p.m. (BLUE form, Court Meeting) and 12:15 p.m. (WHITE form, General Meeting) on 28 October 2026. After that come the meetings on 30 October and the regulatory approvals. The election deadline for the alternative falls one Business day before the court hearing.

Next steps for Spire Healthcare shareholders

With the scheme document published, the takeover of Spire Healthcare (LSE:SPI) moves from agreed terms to a formal vote. The 30 October meetings are the next key test for the 250p offer.